GlucoSenseÂ contains natural ingredients to help support healthy glucose metabolism:
Alpha-Lipoic AcidÂ has been shown to improve blood sugar metabolism, improve blood flow to peripheral nerves, and stimulate the regeneration of nerve fibres. Alpha-Lipoic Acid is used to help treat symptoms of nerve damage in people suffering from Type I and Type II diabetes.
BerberineÂ has been shown to effectively lower glucose levels both while fasting and after a meal in type 2 diabetics. Berberine has also been shown to be as effective as drugs like metformin for lowering elevated blood glucose levels in type 2 diabetics (Yin et al, 2008).
Bitter Melon:Â Bitter Melon has been shown to contain an insulin-like substance that promotes improved blood sugar control.
Chromium:Â Chromium helps maintain healthy glucose levels for people with blood sugar concerns. It helps insulin regulate blood sugar and it enhances insulin absorption.
Bilberry Extract:Â Bilberry Extract contains a substance called glucoquinine, which has the ability to significantly lower blood sugar levels.
Cinnamon:Â Cinnamon has long been used traditionally for the regulation of blood glucose levels. A study by Lu et al (2011) found that supplementation with Chinese cinnamon extract (Cinnamomum aromaticum) significantly improved glucose control and blood lipid parameters in 66 type 2 diabetes patients. The extract was effective even at a low daily dose.
Biotin:Â Biotin is an essential nutrient that plays an important role in glucose metabolism in the body, and deficiencies in biotin have been associated with impaired glucose metabolism. Studies have shown that taking a combination of biotin and chromium picolinate can be highly effective for helping to regulate glucose metabolism. For example, one study of 447 overweight patients with poorly controlled type 2 diabetes has shown that taking a biotin/chromium combination as an adjuvant to regular prescription anti-diabetic medication, improved glycemic control in overweight to obese individuals with type 2 diabetes; especially those patients with poor glycemic control on oral therapy (Albarracin et al, 2008).